Unmissable investment strategy! The Federal Reserve officially enters a new era of interest rate cuts, these 6 industries have the most profitable potential.
Prepare yourself for the interest rate cut cycle.
Jones Trading Initiates Coverage On Intellia Therapeutics With Buy Rating, Announces Price Target of $41
Intellia Therapeutics Analyst Ratings
Reported Earlier Intellia Therapeutics To Present Data From The Phase 2 Study Of NTLA-2002 For The Treatment Of Hereditary Angioedema At The 2024 ACAAI Annual Scientific Meeting; To Host Investor Webcast On October 28, At 8:00 A.m. ET
Small-cap Stocks Have Climbed Recently. Here Are the Ones Most Poised for Further Upside
Looking Into Recursion Pharmaceuticals's Recent Short Interest
Coeur Mining, Medical Properties Trust And RH Are Among Top 7 Mid Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
CareDx Names Keith Kennedy as COO
Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts
10x Genomics Announces Its Chromium Single Cell Gene Expression And Xenium In Situ Platforms Were Used In A Publication, Featured On The Cover Of Cancer Cell, Shedding Light On The Role Of Fibrotic Scars In Glioblastoma Treatment Recurrence
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Ionis Pharmaceuticals Shares Are Trading Lower After the Company Priced Its $500.3 Million Public Offering of 11.5 Million Common Shares at $43.50 per Share.
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Torex Gold Resources Analyst Ratings
Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals
Stephens & Co. Reiterates Overweight on 10x Genomics, Maintains $30 Price Target
Biogen Announces Trial Win for Higher Spinraza Doze
Recursion Pharmaceuticals Analyst Ratings
Recursion Pharmaceuticals Shares Are Trading Lower. The Company Announced Top-line Results of the SYCAMORE Trial for REC-994 in Symptomatic CCM Patients.